In November, 2016, Soupy for Loopy Foundation donated $50,000 to support neuroblastoma research at Dana-Farber Cancer Institute in Boston. As noted in project documents, “The identification of ALK as a targetable protein in neuroblastoma has evolved into the development of small molecule inhibitors of ALK, which are now in pediatric clinical trials. However, the role of ALK as a target for immunotherapy has been largely understudied.” Immunotherapy is the use of medicines to help a patient’s own immune system recognize and destroy cancer cells more effectively (American Cancer Society).
According to Dr. Rani George, principal investigator, “Our goal is to explore the therapeutic potential of an antibody against the ALK receptor in neuroblastoma. We have developed 8G7, an anti-ALK antibody that binds selectively to ALK and causes decreased tumor growth of neuroblastoma models. We propose to validate these preliminary results by expanding the pre-clinical testing of 8G7 in multiple additional neuroblastoma models, both as a single agent and in combination with ALK inhibitors as well as chemotherapy agents commonly used in the treatment of high-risk neuroblastoma. In addition, we will identify the mechanisms through which our anti-ALK antibody kills tumor cells. If successful, ALK antibody-based therapy will be beneficial not only to neuroblastoma patients with tumor ALK mutations, but also to the larger group of patients with tumor ALK overexpression.”
“Soupy for Loopy is committed to funding medical research that will improve survival rates for children diagnosed with neuroblastoma. We are very pleased to assist Dana-Farber and Dr. George in their efforts to do just that” said Sandra Kosko, President of Soupy for Loopy Foundation.
Copyright 2007-2018 Soupy for Loopy Foundation, Inc. All rights reserved.